In this episode, Canadian HIV experts share their thoughts on some of the most important new insights from HIV treatment and prevention research over the past year.Specifically, the faculty discuss treatment strategies for patients with a history of NRTI resistance based on findings from the 2SD and NADIA trials; the latest data informing the use of 2-drug oral and injectable treatment regimens; prevention approaches for HIV and other sexually transmitted infections based on findings from the DoxyPEP, HPTN 083, and HPTN 084 trials; and other emerging innovations in HIV care.Presenters:Jean-Guy Baril, MDAssociate ProfessorFamily MedicineUniversité de MontrealMontreal, Quebec, CanadaAlexander Wong MD, FRCPCAssociate ProfessorDepartment of MedicineUniversity of SaskatchewanRegina, Saskatchewan, CanadaContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare. Link to full program:http://bit.ly/3YD8T4E Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related